ClinicalTrials.gg
Active, not recruitingNCT03891953Updated Oct 19, 2026

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

A Phase 1 interventional study of DKY709 and PDR001 in Carcinoma, Non-Small-Cell Lung, Melanoma and Nasopharyngeal Carcinoma, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 9 sites in 6 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

How we know

Updated Oct 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis — 7 open to participants now, 15 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Novartis.

Enrollment
44th of 92
98 · median 91
Started
2019
with 3 others
Phase 1
34 of 101
6 open now
Primary completion
2027-06
later than 3 of 14 live
Registered
67th of 101
by date

Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is the 44th largest by enrollment of the 92 interventional ones that give a count, is one of 4 that started in 2019, is one of 34 in phase 1, reaches primary completion later than 3 of the 14 other live ones, and was the 67th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, or all of them as a file.
02

Study summary

This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular treatment arm, dose expansion will further assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Melanoma
  • Nasopharyngeal Carcinoma
  • Microsatellite Stable Colorectal Cancer
  • Triple Negative Breast Cancer

Keywords

  • Non-small Cell Lung Cancer
  • Melanoma
  • Nasopharyngeal Carcinoma
  • Microsatellite Stable Colorectal Cancer
  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study.
  2. Patients must be ≥18 years of age at the time of informed consent form (ICF) signature.
  3. Patients with advanced/ cancer who have progressed despite having received standard therapy in the metastatic setting or are intolerant to standard therapy, and for whom no effective standard therapy is available
  4. In expansion: patient with as determined by version 1.1,
  5. Dose escalation, patients must fit into one of the following groups:

    • NSCLC, previously treated with an /PD-L1 therapy
    • Cutaneous Melanoma, previously treated with an anti-PD-1/PD-L1 therapy
    • NPC

    Dose expansion part, patients must fit into one of the following groups:

    • NSCLC with historic documentation of PD-L1 ≥ 1%. Patients must have progressive disease after having experienced at least 4 months of investigator-assessed disease stability or response on prior anti-PD-L1-containing therapy
    • Cutaneous Melanoma, previously treated with anit-PD-1/PD-L1 therapy. Patients should have documented progression following anti-PD-1/PD-L1 therapy.
    • NPC, naive to anti-PD-1/PD-L1 therapy
    • mssCRC, naive to anti-PD-1/PD-L1 therapy
    • TNBC, naive to anti-PD-1/PD-L1 therapy
  6. Performance Status ≤ 1
  7. Patients must have a site of disease amenable to core needle , and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy at baseline, and during therapy on the study. Exceptions may be considered after documented discussion with Novartis.

Exclusion criteria

Exclusion Criteria:

  1. Presence of symptomatic central nervous system (CNS) , or that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of within 2 weeks prior to study entry. Patients with treated brain metastases should be neurologically stable for at least 4 weeks prior to study entry and off steroids for at least 2 weeks before administration of any study treatment.
  2. History of severe reactions to any ingredient of study drug(s) or other mAbs and/or their .
  3. Patient with out of range laboratory values defined as:

    • (calculated using Cockcroft-Gault formula, or measured) \< 40 mL/min
    • Total > 1.5 x , except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN
    • (ALT) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if ALT > 5 x ULN
    • Aspartate aminotransferase (AST) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if AST > 5 x ULN
    • (ANC) \< 1.0 x 109/L
    • count \< 75 x 109/L (growth factor or transfusion support may not be used to meet entry criterion)
    • (Hgb) \< 8 g/dL (growth factor or transfusion support may not be used to meet entry criterion)
    • Magnesium, calcium or phosphate abnormality > grade 1
    • Potassium abnormality CTCAE ≥ grade 1; supplementation to meet eligibility criteria is acceptable
  4. cardiac disease or impaired cardiac function, including any of the following:

    • Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment ( grade ≥ 2), uncontrolled hypertension or clinically significant arrhythmia
    • On screening: > 450 msec (male), or > 460 msec (female)
    • QTc not assessable
    • Congenital long QT syndrome
    • History of familial long QT syndrome or known family history of as Torsades de Pointes
    • Acute myocardial infarction or unstable angina pectoris \< 3 months prior to study entry
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    DKY709

    DKY709 monotherapy

    Drug: DKY709

  • Experimental
    DKY709 + PDR001

    Combination therapy with DKY709 and PDR001

    Drug: DKY709 · Drug: PDR001

Interventions

  • DrugDKY709

    Novel immunomodulatory agent

  • DrugSpartalizumabStudies of SpartalizumabSpartalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2

    Also known as: Spartalizumab

06

What researchers measure

Primary outcomes

  1. Safety of DKY709 single agent treatment or DKY709 in combination with PDR001.

    Incidence and severity of AEs and SAEs

    Time frame: 24 months

  2. incidence of Dose Limiting Toxicities (DLTs)

    The incidence of DLTs during the first cycle of treatment with single agent DKY709 or the combination of DKY709 with PDR001.

    Time frame: 1 Month

  3. Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.

    Incidence and severity of AEs and SAEs

    Time frame: 24 months

Secondary outcomes

  1. AUC of DKY709 and PDR001

    AUC

    Time frame: 24 months

  2. Cmax of DKY709 and PDR001

    Cmax

    Time frame: 24 months

  3. Tmax of DKY709 and PDR001

    Tmax

    Time frame: 24 months

  4. Half-life of DKY709 and PDR001

    Half-life

    Time frame: 24 months

  5. Progression Free Survival (PFS)

    Determine PFS in each part of the study

    Time frame: 24 months

  6. Best Overall Response (BOR)

    Determine BOR in each part of the study

    Time frame: 24 months

  7. Duration of Response (DOR)

    Determine DOR in each part of the study

    Time frame: 24 months

  8. Time to Progression (TTP)

    Determine TTP in each part of the study

    Time frame: 24 months

07

Study locations

9 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Chuo Ku, Tokyo 1040045, Japan
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Jun 2027, 97 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 97 months is above that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Oct 2026 → Jun 2027 and completion Oct 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2019
First posted
Mar 27, 2019
StartActual
May 7, 2019
Primary completionEst.
Jun 25, 2027was Oct 2026
CompletionEst.
Jun 25, 2027was Oct 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Tennessee Oncology · Nashville, United States
Show 1 removed
  • Sarah Cannon Research Institute · Nashville, United States
Oct 19, 2026
Primary completion
Oct 30, 2026→Jun 25, 2027
Oct 19, 2026
Study completion
Oct 31, 2026→Jun 25, 2027
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    1 site added, 1 site removed
    Show site
    • Tennessee Oncology · Nashville, United States
    Show 1 removed
    • Sarah Cannon Research Institute · Nashville, United States
    Primary completion Oct 30, 2026→Jun 25, 2027
    Study completion Oct 31, 2026→Jun 25, 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03891953
Responsible party
Sponsor
First posted
Mar 27, 2019
Start date
May 7, 2019
Primary completion
Jun 25, 2027 (estimated)
Completion
Jun 25, 2027 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion